Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223294 | 1.00 | AR (0.40) | ARMAOAMAOBMLYCDPDK1 | |
| SCHEMBL223737 | 0.92 | AR (0.40) | ARPGR | |
| SCHEMBL223736 | 0.92 | AR (0.40) | ARPGR | |
| SCHEMBL223991 | 0.87 | AR (0.45) | ARMAOAMAOBPDK1PDK2 | |
| SCHEMBL223992 | 0.87 | AR (0.45) | ARMAOAMAOBPDK1PDK2 | |
| SCHEMBL1364689 | 0.85 | AR (0.38) | ARMAOAMAOBMLYCDPGR | |
| SCHEMBL1364954 | 0.85 | AR (0.38) | ARMAOAMAOBMLYCDPGR | |
| SCHEMBL223682 | 0.80 | AR (0.38) | ARPGR | |
| SCHEMBL223681 | 0.80 | AR (0.38) | ARPGR | |
| SCHEMBL220763 | 0.80 | AR (0.49) | ARPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004270-A1 | Selective Androgen Receptor Modulators | AR, NR3C2, NR5A1 | AR 1/4885MAOA 4102/4885MAOB 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.